CareDx announced new data from its KOAR study, presented at ASN Kidney Week 2026, demonstrating that elevated AlloSure Kidney test levels in transplant patients with rejection significantly increase the risk of adverse graft outcomes. This reinforces the clinical utility and market position of CareDx's non-invasive diagnostic solution for transplant monitoring.
CareDx announced new findings from its KOAR study at a major medical conference, ASN Kidney Week 2026. The data indicates that their AlloSure Kidney test can predict a nearly 3-fold increased risk of adverse graft outcomes in transplant patients with certain types of rejection, highlighting the test's clinical utility. This is significant for CareDx as it provides further scientific validation for a core product, potentially increasing adoption and market share. For traders, this reinforces the company's competitive advantage in the transplant diagnostics space, offering a long-term positive signal for CDNA, though the immediate market impact might be moderate as it's an incremental data release rather than a new product launch or financial update.